GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,972 DKK | -1.79% |
|
-1.74% | -8.49% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Presenter SpeechMatthew Harrison (Analysts)All right. Perfect. I think we are ready to go. Goo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
2,008
DKK
Average target price
2,434
DKK
Spread / Average Target
+21.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.49% | 18.68B | |
| -1.81% | 105B | |
| +3.48% | 97.5B | |
| +1.86% | 22.19B | |
| -16.56% | 21.33B | |
| -42.33% | 16.6B | |
| -21.09% | 14.52B | |
| +5.11% | 14.09B | |
| +22.00% | 10.99B | |
| -23.93% | 8.63B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 08
